In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma

Dong, Jianjun; Zhou, Ying; Liu, Y.T.; Zhang, Z.W.; Zhou, Xiaojun; Wang, H.J.; Liao, Lin

doi:10.1016/j.mce.2013.02.001

Cited by 14 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Doxorubicin has been the most frequently used drug, but it is only affective on differentiated TC tumours (Jeglum and Whereat, 1983;Ogilvie et al, 1989). Studies using cisplatine and nevirapine have reported similar results (Fineman et al, 1998;Muscella et al, 2009;Dong et al, 2013). On the other hand, chemotherapy after thyroidectomy has been reported to not provide a survival benefit (Nadeu et al, 2011;Tuohy et al, 2012).…”

Section: Introductionmentioning

confidence: 90%

Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome

Castillo¹,

Pessina²,

Hall³

et al. 2016

Open Vet J.

View full text Add to dashboard Cite

The objective of the present study was to compare the effects of isotretinoin 9-cis (RA9-cis) as a post-surgery treatment of thyroid carcinoma to a traditional treatment (doxorubicin) and no treatment. Owners who did not want their dogs to receive treatment were placed into the control group A (GA; n=10). The remaining dogs were randomly placed into either group B (GB; n=12) and received doxorubicin at a dose of 30 mg/m 2 every three weeks, for six complete cycles or group C (GC; n=15) and treated with RA9-cis at a dose of 2 mg/kg/day for 6 months. The time of the recurrence was significantly shorter in the GA and GB compared to GC (P=0.0007; P=0.0015 respectively), while we did not detect differences between GA and GB. The hazard ratio of recurrence between GA and GB compared to GC were 7.25 and 5.60 times shorter, respectively. We did not detect any differences between the other groups. The risk ratio of recurrence was 2.0 times higher in GA compared to GC and 2.1 times higher in GB compared to GC. The type of carcinoma had an effect on time of survival with follicular carcinomas having an increased mean survival time than follicular-compact carcinomas (P<0.0001) and follicular-compact carcinomas had a longer mean survival time than compact carcinomas. The interaction among treatment and type was significant, but survival time in follicular carcinomas did not differ between treatments. In follicular-compact carcinomas the survival time of GC was greater than GB (P<0.05), but we did not detect a difference between GA and GB. In conclusion, this study shows that the use of surgery in combination with RA9-cis treatment significantly increases survival rate and decreases the time to tumor recurrence when compared to doxorubicin treated or untreated dogs. The histological type of carcinoma interacted with treatment for time to recurrence and survival time, with more undifferentiated carcinomas having a worse prognosis than differentiated carcinomas.

show abstract

Section: Introductionmentioning

confidence: 90%

Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome

Castillo¹,

Pessina²,

Hall³

et al. 2016

Open Vet J.

View full text Add to dashboard Cite

show abstract

“…1C), including the appearance of dendritic-like extensions and increased adhesion to the plate surface, distinctive of differentiating melanoma (see [78] for an in-depth characterization), are accompanied by global alterations of the transcriptome of coding and non-coding sequences, as will be seen below. Several laboratories have independently confirmed these conclusions in studies of various human tumorigenic cell lines treated with RT inhibitors, both of the nonnucleoside [80, 81, 82] and the nucleoside type [83, 84, 85]. …”

Section: Introductionmentioning

confidence: 92%

Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression

et al. 2014

View full text Add to dashboard Cite

LINE-1 retrotransposons encode the reverse transcriptase (RT) enzyme, required for their own mobility, the expression of which is inhibited in differentiated tissues while being active in tumors. Experimental evidence indicate that the inhibition of LINE-1-derived RT restores differentiation in cancer cells, inhibits tumor progression and yields globally reprogrammed transcription profiles. Newly emerging data suggest that LINE-1-encoded RT modulates the biogenesis of miRNAs, by governing the balance between the production of regulatory double-stranded RNAs and RNA:DNA hybrid molecules, with a direct impact on global gene expression. Abnormally high RT activity unbalances the transcriptome in cancer cells, while RT inhibition restores ‘normal’ miRNA profiles and their regulatory networks. This RT-dependent mechanism can target the myriad of transcripts - both coding and non-coding, sense and antisense - in eukaryotic transcriptomes, with a profound impact on cell fates. LINE-1-encoded RT emerges therefore as a key regulator of a previously unrecognized mechanism in tumorigenesis

show abstract

“…Expression of the sodium iodide symporter is often absent, thereby significantly reducing the functional effectiveness of radioiodine ablation and treatment. Current therapeutic approaches include the redifferentiation of these tumours with various agents to improve treatability (Schmutzler & Kohrle 2000, Kang et al 2011, Dong et al 2013. In view of the inherent lack of expression of normal TSH receptors in anaplastic thyroid cancers, serum TSH concentrations have not been studied in relation to the diagnosis or progression of these tumours.…”

Section: Genetic Factorsmentioning

confidence: 99%

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Nieto¹,

Boelaert²

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Differentiated thyroid cancer is the most common endocrine malignancy and the incidence is increasing rapidly worldwide. Appropriate diagnosis and post-treatment monitoring of patients with thyroid tumours are critical. Fine needle aspiration cytology remains the gold standard for diagnosing thyroid cancer, and although there have been significant refinements to this technique, diagnostic surgery is often required for patients suspected to have malignancy. Serum thyroid-stimulating hormone (TSH) is higher in patients with malignant thyroid nodules than in those with benign disease, and TSH is proportionally increased in more aggressive tumours. Importantly, we have shown that the pre-operative serum TSH concentration independently predicts the presence of malignancy in subjects presenting with thyroid nodules. Establishing the use of TSH measurements in algorithms identifying high-risk thyroid nodules in routine clinical practice represents an exciting, cost-efficient and non-invasive approach to optimise thyroid cancer diagnosis. Binding of TSH to receptors on thyrocytes stimulates a number of growth promoting pathways both in normal and malignant thyroid cells, and TSH suppression with high doses of levothyroxine is routinely used after thyroidectomy to prevent cancer recurrence, especially in high-risk tumours. This review examines the relationship between serum TSH and thyroid cancer and reflects on the clinical potential of TSH measurements in diagnosis and disease monitoring.

show abstract

In vitro evaluation of the therapeutic potential of nevirapine in treatment of human thyroid anaplastic carcinoma

Cited by 14 publications

References 22 publications

Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome

Post-surgical treatment of thyroid carcinoma in dogs with retinoic acid 9 cis improves patient outcome

Regulatory roles of LINE-1-encoded reverse transcriptase in cancer onset and progression

WOMEN IN CANCER THEMATIC REVIEW: Thyroid-stimulating hormone in thyroid cancer: does it matter?

Contact Info

Product

Resources

About